According to the World Health Organization (WHO), at present, cancer is the second leading cause of death, worldwide. The National Cancer Institute (NCI) has estimated that, by 2030, over 22 million individuals are likely to be diagnosed with various types of cancer, in the US alone. As a result of the growing patient population affected by this disease, there is a rise in the demand for effective treatment modalities. The conventional approaches, such as chemotherapy, surgery and radiation therapy, employed for the treatment of oncological indication(s) are considered to be inadequate, specifically for late-stage cancers. Therefore, in recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. However, certain limitations are associated with the aforementioned class of therapies as well; they have been demonstrated to have off-target and toxic side effects, including cytokine release syndrome and neurotoxicity. This has further led to significant research initiatives aimed at identifying target specific drug candidates. Among such initiatives, CD47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker. Published literature further indicates that tumor growth and metastasis can be inhibited by blocking the interaction between CD47 and the signal-regulating protein alpha (SIRPα).

Leave a Reply